Background
Kidney failure with replacement therapy and hemodialysis are associated with a decrease in quality of life (QOL). Self-reported QOL symptoms are not always prioritized by the medical team, potentially leading to conflicting priorities with patients. Electronic patient-reported outcome measures (ePROMs) allow physicians to better identify these symptoms. The objective was to describe the prevalence of symptoms self-reported by hemodialysis (HD) patients.
Methods
A multicenter cross-sectional study was conducted in three HD centers. Patients were included if they were 18 years old or over treated with HD for at least 3 months in a center. Data were collected by the patient via a self-administered ePROMs questionnaire. Data included patient characteristics, post-dialysis fatigue and intensity, recovery time after a session, perceived stress, impaired sleep the day before the dialysis session, current state of health and the change from the past year. A multivariate analysis was conducted to identify relations between symptoms.
Results
In total, we included 173 patients with a mean age of 66.2 years, a mean ± SD hemodialysis duration of 48.9 ± 58.02 months. The prevalence of fatigue was 72%. 66% had a high level of stress (level B or C). Recovery time was more than 6 h after a HD session for 25% of patients and 78% declared they had a better or unchanged health status than the previous year. Sleep disturbance was associated with cardiovascular comorbidities (OR 5.08 [95% CI, 1.56 to 16.59], p = 0.007).
Conclusions
Fatigue and stress were the main symptoms reported by HD patients. The patient’s care teams should better consider these symptoms.
Background: End Stage renal disease (ESRD) and hemodialysis are associated with a decrease in quality of life (QOL). Self-reported QOL symptoms are not always prioritized by the medical team, potentially leading to conflicting priorities with patients. Electronic patient-reported outcome measures (ePROMs) allow physicians to better identify these symptoms. The objective was to describe the prevalence of symptoms self-reported by hemodialysis (HD) patients.Methods: A multicenter cross-sectional study was conducted in three HD centers. Patients were included if they were 18 years old or over and treated with HD for at least three months in a center. Data were collected by the patient via a self-administered ePROMs questionnaire. Data included patient characteristics, post-dialysis fatigue and intensity, recovery time after a session, perceived stress, impaired sleep the day before the dialysis session, current state of health, and the one-year change. Results: In total, we included 173 patients with a mean age of 66.2 years, a mean ± SD hemodialysis duration of 48.9 ± 58.02 months. They were mainly treated in self-dialysis unit (67%) with at least one comorbidity (72.5%). The prevalence of fatigue was 72.1%. 66.4% had a high level of stress (level B or C). Recovery time was more than 6 hours after a HD session for 24.9% of patients and 78 % declared they had a better or unchanged health status than the previous year. Sleep disturbance was associated with cardiovascular comorbidities. Conclusions: Fatigue and stress were the main symptoms reported by HD patients. The patient’s care teams should better consider these symptoms.Trial registration: Commission Nationale de l'Informatique et des Libertés (CNIL): N° 2214737V0, Date First Registered: 2019-08-20. The CPP (Patient Protection Committee) Ile-de-France VII (2019-12-26) in accordance with French regulations N° ID-RCB: 2019-AO1373-54. Date First Registered: 2019-08-19.All methods were carried out in accordance with the relevant guidelines and regulations. Informed consent was obtained from all subjects, no subjects were under 18 years of age
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.